

2014 AHA/ACC guideline for the management of patients with valvular heart disease

A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons

Writing Committee Members^a:	Rick A. Nishimura, Co-Chair, MD, MACC, FAHA, ^b Catherine M. Otto, Co-Chair, MD, FACC, FAHA, ^b Robert O. Bonow, MD, MACC, FAHA, ^b Blase A. Carabello, MD, FACC, ^{a,b} John P. Erwin III, MD, FACC, FAHA, ^c Robert A. Guyton, MD, FACC, ^{a,d} Patrick T. O’Gara, MD, FACC, FAHA, ^b Carlos E. Ruiz, MD, PhD, FACC, ^b Nikolaos J. Skubas, MD, FASE, ^e Paul Sorajja, MD, FACC, FAHA, ^f Thoralf M. Sundt III, MD, ^{a,g,h} and James D. Thomas, MD, FASE, FACC, FAHA ⁱ
ACC/AHA Task Force Members:	Jeffrey L. Anderson, Chair, MD, FACC, FAHA, Jonathan L. Halperin, Chair-Elect, MD, FACC, FAHA, Nancy M. Albert, PhD, CCNS, CCRN, FAHA, Biykem Bozkurt, MD, PhD, FACC, FAHA, Ralph G. Brindis, MD, MPH, MACC, Mark A. Creager, MD, FACC, FAHA, ^j Lesley H. Curtis, PhD, FAHA, David DeMets, PhD, Robert A. Guyton, MD, FACC, ^j Judith S. Hochman, MD, FACC, FAHA, Richard J. Kovacs, MD, FACC, FAHA, E. Magnus Ohman, MD, FACC, Susan J. Pressler, PhD, RN, FAHA, Frank W. Sellke, MD, FACC, FAHA, Win-Kuang Shen, MD, FACC, FAHA, William G. Stevenson, MD, FACC, FAHA, ^j and Clyde W. Yancy, MD, FACC, FAHA ^j

Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply^a; see [Appendix 1](#) for recusal information; ACC/AHA representative^b; ACC/AHA Task Force on Performance Measures liaison^c; ACC/AHA Task Force on Practice Guidelines liaison^d; Society of Cardiovascular Anesthesiologists representative^e; Society for Cardiovascular Angiography and Interventions representative^f; American Association for Thoracic Surgery representative^g; Society of Thoracic Surgeons representative^h; American Society of Echocardiography representativeⁱ; former Task Force member during the writing effort.^j

This document was approved by the American College of Cardiology Board of Trustees and the American Heart Association Science Advisory and Coordinating Committee in January 2014.

The American College of Cardiology requests that this document be cited as follows: Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton RA, O’Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM III, Thomas JD. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Thorac Cardiovasc Surg*. 2014;148:e1-132.

This article has been copublished in *Circulation*, the *Journal of the American College of Cardiology*, and the *Journal of Thoracic and Cardiovascular Surgery*.

Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.cardiosource.org), the American Heart Association (my.americanheart.org), and the American Society of Thoracic Surgery (<http://www.aats.org>). For copies of this document, please contact the Elsevier Inc. Reprint Department: fax, 212-633-3820; E-mail: reprints@elsevier.com.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Association for Thoracic Surgery. Requests may be completed online via the Elsevier site (<http://www.elsevier.com/authors/obtaining-permission-to-re-use-elsevier-material>).

0022-5223/\$36.00

Copyright © 2014 by The American Association for Thoracic Surgery, the American College of Cardiology Foundation, and the American Heart Association.

<http://dx.doi.org/10.1016/j.jtcvs.2014.05.014>

Abbreviations and Acronyms

2D	= 2-dimensional
3D	= 3-dimensional
ACE	= angiotensin-converting enzyme
AF	= atrial fibrillation
ARB	= angiotensin-receptor blocker
aPTT	= activated partial thromboplastin time
AR	= aortic regurgitation
AS	= aortic stenosis
AVR	= aortic valve replacement
BP	= blood pressure
CABG	= coronary artery bypass graft
CAD	= coronary artery disease
CMR	= cardiac magnetic resonance
COR	= Class of Recommendation
CT	= computed tomography
ECG	= electrocardiogram
HF	= heart failure
HIV	= human immunodeficiency virus
IE	= infective endocarditis
INR	= international normalized ratio
LA	= left atrium
LMWH	= low-molecular-weight heparin
LOE	= Level of Evidence
LV	= left ventricular
LVEF	= left ventricular ejection fraction
LVESD	= left ventricular end-systolic dimension
MI	= myocardial infarction
MR	= mitral regurgitation
MS	= mitral stenosis
MVR	= mitral valve replacement
NYHA	= New York Heart Association
NVE	= native valve endocarditis
PR	= pulmonic regurgitation
PROM	= predicted risk of mortality
PVE	= prosthetic valve endocarditis
RCT	= randomized controlled trial
RV	= right ventricular
TAVR	= transcatheter aortic valve replacement

TABLE OF CONTENTS

Preamble	e4
1 Introduction	e6
1.1 Methodology and Evidence Review	e6
1.2 Organization of the Writing Committee	e7
1.3 Document Review and Approval	e7
1.4 Scope of the Guideline	e7
2 General Principles	e7
2.1 Evaluation of the Patient With Suspected VHD	e7
2.2 Definitions of Severity of Valve Disease	e8
2.3 Diagnosis and Follow-up	e8

2.3.1 Diagnostic Testing—Initial Diagnosis: Recommendation	e9
2.3.2 Diagnostic Testing—Changing Signs or Symptoms: Recommendation	e9
2.3.3 Diagnostic Testing—Cardiac Catheterization: Recommendation	e9
2.3.4 Diagnostic Testing—Cardiac Catheterization: Recommendation	e10
2.3.5 Diagnostic Testing—Exercise Testing: Recommendation	e10
2.4 Basic Principles of Medical Therapy	e10
2.4.1 Secondary Prevention of Rheumatic Fever: Recommendation	e11
2.4.2 IE Prophylaxis: Recommendations	e11
2.5 Evaluation of Surgical and Interventional Risk	e13
2.6 The Heart Valve Team and Heart Valve Centers of Excellence: Recommendations	e13
3 Aortic Stenosis	e15
3.1 Stages of Valvular AS	e15
3.2 Aortic Stenosis	e16
3.2.1 Diagnosis and Follow-Up	e16
3.2.1.1 Diagnostic testing—initial diagnosis: Recommendations	e16
3.2.1.2 Diagnostic testing—changing signs or symptoms	e18
3.2.1.3 Diagnostic testing—routine follow-up	e19
3.2.1.4 Diagnostic testing—cardiac catheterization	e19
3.2.1.5 Diagnostic testing—exercise testing: Recommendations	e19
3.2.2 Medical Therapy: Recommendations	e20
3.2.3 Timing of Intervention: Recommendations	e21
3.2.4 Choice of Intervention: Recommendations	e24
4 Aortic Regurgitation	e27
4.1 Acute AR	e27
4.1.1 Diagnosis	e27
4.1.2 Intervention	e27
4.2 Stages of Chronic AR	e27
4.3 Chronic AR	e28
4.3.1 Diagnosis and Follow-up	e28
4.3.1.1 Diagnostic testing—initial diagnosis: Recommendations	e28
4.3.1.2 Diagnostic testing—changing signs or symptoms	e28
4.3.1.3 Diagnostic testing—routine follow-up	e28
4.3.1.4 Diagnostic testing—cardiac catheterization	e30
4.3.1.5 Diagnostic testing—exercise testing	e30
4.3.2 Medical Therapy: Recommendations	e30
4.3.3 Timing of Intervention: Recommendations	e31

Download English Version:

<https://daneshyari.com/en/article/2980733>

Download Persian Version:

<https://daneshyari.com/article/2980733>

[Daneshyari.com](https://daneshyari.com)